| ||Audit Committee||Compensation Committee||Nominating and Corporate Governance Committee|
|Russell J. Cox |
|Russell J. Cox|
Director, Executive Vice President and Chief Operating Officer of Jazz Pharmaceuticals
Russell J. Cox, is Executive Vice President and Chief Operating Officer of Jazz Pharmaceuticals. He has served in a variety of escalating senior management roles since joining the company in 2010, including Executive Vice President and Chief Commercial officer from March 2012 to May 2014. From January 2009 to January 2010, he was Senior Vice President and Chief Commercial Officer of Ipsen Group and from 2007 until December 2008, he was Vice President of Marketing at Tercica, Inc. (acquired by Ip...
Director, Senior Vice President and Chief Financial Officer of Serepta Therapeutics
Sandy Mahatme is Senior Vice President and Chief Financial Officer of Serepta Therapeutics. From January 2006 to November 2012, Mr. Mahatme worked at Celgene Corporation, a biopharmaceutical company, where he served in various roles, including Senior Vice President of Corporate Development, Senior Vice President of Finance, Corporate Treasurer and Head of Tax. While at Celgene, Mr. Mahatme built the treasury and tax functions before establishing the Corporate Development Department, focused on s...
|Dr. Anthony Quinn |
|Dr. Anthony Quinn|
Director, Executive Vice President, Chief Medical Officer and Head of Research & Development at Synageva Biopharma Corp.
Dr. Quinn most recently served as Executive Vice President, Chief Medical Officer and Head of Research & Development at Synageva Biopharma Corp. until its acquisition by Alexion Pharmaceuticals in 2015....
|Armen Shanafelt, Ph.D. |
|Armen Shanafelt, Ph.D.|
Director, Lilly Ventures
Dr. Shanafelt brings over 24 years of experience in the pharmaceutical, biotechnology, and diagnostic businesses to Lilly Ventures. Previous to joining Lilly Ventures, Armen was CSO responsible for the generation of the early biotherapeutic pipeline for Eli Lilly and Company, spanning the therapeutic areas of oncology, endocrine, and neuroscience. During his seven years with Lilly, the biotherapeutic group delivered over 20 molecules into clinic development. Dr. Shanafelt received his B.S. Degre...